4-Year Results: Tislelizumab Plus Chemo for Esophageal Cancer
In a groundbreaking development within the arena of oncology, new data emerging from the phase 2 TD-NICE clinical trial reveals ...
In a groundbreaking development within the arena of oncology, new data emerging from the phase 2 TD-NICE clinical trial reveals ...
Pancreatic cancer remains one of the most formidable challenges in oncology, notorious for its dismal five-year survival rate of just ...
HOUSTON — At the forefront of cancer research, scientists from The University of Texas MD Anderson Cancer Center have made ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine